DOCMORRIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85.55 CHF | +3.63% |
|
+4.58% | +16.00% |
| 04-23 | DOCMORRIS : Deutsche Bank remains its Buy rating | ZD |
| 04-19 | DOCMORRIS : Hauck & Aufhauser gives a Buy rating | ZD |
| Sales 2024 * | 1.18B 1.29B 1.77B | Sales 2025 * | 1.61B 1.76B 2.4B | Capitalization | 1.01B 1.1B 1.5B |
|---|---|---|---|---|---|
| Net income 2024 * | -84M -91.85M -126M | Net income 2025 * | -20M -21.87M -29.89M | EV / Sales 2024 * | 1.06 x |
| Net Debt 2024 * | 247M 270M 369M | Net Debt 2025 * | 280M 307M 419M | EV / Sales 2025 * | 0.8 x |
| P/E ratio 2024 * |
-12.6
x | P/E ratio 2025 * |
-55.2
x | Employees | 1,453 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on DocMorris AG
More press releases
More news
| 1 day | +3.63% | ||
| 1 week | +4.58% | ||
| Current month | -5.52% | ||
| 1 month | +4.14% | ||
| 3 months | +10.46% | ||
| 6 months | +129.23% | ||
| Current year | +16.00% |
1 week
80.45
88.35
1 month
80.4598.85
Current year
68.80101.60
1 year
28.52101.60
3 years
23.02431.00
5 years
23.02514.00
10 years
23.02514.00
| Managers | Title | Age | Since |
|---|---|---|---|
Walter Hess
CEO | Chief Executive Officer | 59 | 14-12-31 |
| Founder | 66 | 93-04-05 | |
Marcel Ziwica
DFI | Director of Finance/CFO | 49 | 00-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 10-03-31 | |
Florian Seubert
BRD | Director/Board Member | 51 | 19-05-22 |
| Founder | 66 | 93-04-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +2.14% | - | |
| 0.00% | 26 M€ | -4.26% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 85.55 | +3.63% | 64,718 |
| 24-04-25 | 82.55 | -4.29% | 73,122 |
| 24-04-24 | 86.25 | +2.80% | 104,125 |
| 24-04-23 | 83.9 | +1.33% | 52,640 |
| 24-04-22 | 82.8 | +1.22% | 81,398 |
Delayed Quote Swiss Exchange, April 26, 2024 at 11:31 am
More quotes
Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The Company operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.
Sector
Drug Retailers
Calendar
2024-05-02
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
85.55
CHF
Average target price
99.24
CHF
Spread / Average Target
+16.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.00% | 1.1B | |
| -31.97% | 10.84B | |
| +8.14% | 6.04B | |
| -11.41% | 5.86B | |
| -30.42% | 6.06B | |
| -0.88% | 4.71B | |
| +52.19% | 4.29B | |
| -12.31% | 3.61B | |
| -14.86% | 3.33B | |
| -6.93% | 3.01B |
- Stock Market
- Equities
- ROSE Stock
